Mapletree Investments' profit after tax and minority interest, or PATMI, rose 26% in the fiscal year ended March 31 to SG$285.6 million from SG$227.2 million a year earlier, according to a release by the REIT on Tuesday.
The REIT reported a stable revenue of SG$2.2 billion during the period and booked total gross proceeds of SG$4.2 billion.
In fiscal 2026, the REIT completed 13 development projects and as of March 31, it had SG$5.4 billion worth of projects under development.
Vibrant Group (SGX:BIP) named Don Tang Fook Yuen as the company's interim chief executive officer, effective June 2, according to a same-day filing with the Singapore Exchange.Shares of the integrated logistics company were down nearly 1% in Wednesday trading.The company will continue its search for a permanent CEO, the filing added.
Semiconductor and electronics test company AEM (SGX:AWX) issued and allotted 573,655 shares to its employees pursuant to the vesting of share awards granted under the restricted share option plan, according to a filing with the Singapore Exchange on Tuesday.Shares of the company were up over 4% in Wednesday trading.The new shares are expected to be listed and quoted on June 4.Following the issuance, the total number of issued and paid-up share capital stands at 319.5 million shares.
CSPC Pharmaceutical Group (HKG:1093) said currently available clinical data for its drug candidate SYS6043 indicates it could become a treatment option for multiple tumor types, according to a Tuesday filing with the Hong Kong bourse.According to the company, the medicine demonstrated "favorable anti-tumor activity" in subjects enrolled in an open-label, phase 1/2 clinical study in China.Among the 533 evaluable patients, the objective response rate was 41.8% while the median duration of response stood at 6.9 months. The disease control rate among the patients was assessed at 81.4%.Based on the results, the firm said it would advance related studies of the drug in ovarian cancer, breast cancer, and small cell lung cancer.